Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database

Elias JabbourDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Correspondence[email protected]

Matthias StelljesDepartment of Medicine, Hematology and Oncology, Universitätsklinikum Münster, Münster, Germany;

Anjali S. AdvaniDepartment of Hematology/Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA;

Daniel J. DeAngeloDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;

Nicola GökbugetDepartment of Medicine II, University Hospital, Goethe University, Frankfurt, Germany;

David I. MarksBristol Haematology & Oncology Centre, University Hospitals Bristol NHS Trust, Bristol, UK;

Wendy StockSection of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA;

Susan O’BrienChao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA, USA;

Ryan D. CassadayDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA;;Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;

Tao WangGlobal Product Development – Oncology, Pfizer Inc, Cambridge, MA, USA;

Alexander NeuhofPfizer Pharma GmbH, Berlin, Germany

Erik VandendriesGlobal Product Development – Oncology, Pfizer Inc, Cambridge, MA, USA;

Hagop KantarjianDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA;

show all

Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database

Supplemental Material

Supplemental Material

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database

Supplemental Material

Supplemental Material

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date